不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:ETS1 Function in Leukemia and Lymphoma.
ETS1 Function in Leukemia and Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
ETS proto-oncogene 1(ETS1)是一种转录因子(TF),在淋巴细胞的发育和功能中起关键作用。ETS1 的表达在 T 细胞、自然杀伤(NK)细胞和 B 细胞的分化与活化过程中受到严格调控。它也被描述为多种实体瘤和血液系统恶性肿瘤中的癌基因。在血液系统恶性肿瘤中,其在 T 细胞急性淋巴细胞白血病(T-ALL)、成人 T 细胞白血病/淋巴瘤(ATLL)和弥漫性大 B 细胞淋巴瘤(DLBCL)中的作用研究最为深入。这些恶性肿瘤中 ETS1 的异常表达主要由染色体扩增和增强子驱动的转录调控所驱动,从而促进 ETS1 转录程序。ETS1 还协助异常表达或活化的转录复合物驱动致癌通路。
总体而言,ETS1 在这些恶性肿瘤中发挥调控细胞生长、分化、信号传导、刺激应答和病毒相互作用的功能。在部分淋巴瘤类型中,ETS1 也被提示具有抑癌作用,强调了细胞背景对 ETS1 功能的重要性。目前正在开展研究,以进一步表征 ETS1 失调在血液系统恶性肿瘤中的临床意义,进一步解析结合复合物和转录靶点,并确定有效的治疗靶向策略。
ETS proto-oncogene 1 (ETS1) is a transcription factor (TF) critically involved in lymphoid cell development and function. ETS1 expression is tightly regulated throughout differentiation and activation in T-cells, natural killer (NK) cells, and B-cells. It has also been described as an oncogene in a range of solid and hematologic cancer types. Among hematologic malignancies, its role has been best studied in T-cell acute lymphoblastic leukemia (T-ALL), adult T-cell leukemia/lymphoma (ATLL), and diffuse large B-cell lymphoma (DLBCL). Aberrant expression of ETS1 in these malignancies is driven primarily by chromosomal amplification and enhancer-driven transcriptional regulation, promoting the ETS1 transcriptional program.
ETS1 also facilitates aberrantly expressed or activated transcriptional complexes to drive oncogenic pathways. Collectively, ETS1 functions to regulate cell growth, differentiation, signaling, response to stimuli, and viral interactions in these malignancies.
A tumor suppressor role has also been indicated for ETS1 in select lymphoma types, emphasizing the importance of cellular context in ETS1 function. Research is ongoing to further characterize the clinical implications of ETS1 dysregulation in hematologic malignancies, to further resolve binding complexes and transcriptional targets, and to identify effective therapeutic targeting approaches.
MEMBER ACCOUNT
登录成功会直接打开下一页。